INCY News and Press, Incyte Corporation From 05/18/22

Popularity isn't a guarantee of success in the stock market. Some well-known companies can be lousy investment choices while lesser-known ones can boast much more promising prospects. That's why it's worth looking past the hype to dig deeper and find stocks that may not be household names b...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Shares of CTI BioPharma (NASDAQ: CTIC) moved sharply higher after the drugmaker reported first-quarter results Friday morning. Investors were pleased with the initial sales figures for Vonjo, its first approved drug, and pushed the stock price 20.8% higher as of 11:22 a.m. ET. O...

The clinical-stage biotech Concert Pharmaceuticals (NASDAQ:CNCE) announced on Thursday that the U.S. patent office upheld the validity of a key patent of its lead product candidate CTP-543 following a petition filed by rival biotech Incyte Corporation (INCY). Concert (CNCE) shares recorded th...

ARKG has made a massive reshuffling of its portfolio in the past one year, but that is yet to generate results. ARKG had a steep price fall over the past one month, and had a poor price performance over the short and medium term. ARKG recorded a 52-week low price on 10th May, 2022...

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 PR Newswire OLUMIANT is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring va...

The European Commission (EC) approved Novartis (NYSE:NVS) and Incyte's (INCY) Jakavi (ruxolitinib) to treat patients aged 12 years and older with acute or chronic graft-versus-host disease (GVHD) who have inadequate response to corticosteroids or other systemic therapies. "Jakavi, w...

Jakavi ® (ruxolitinib) is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GVHD) 1,2 In clinical trials, Jakavi demonstrated superiority versus...

The following slide deck was published by Incyte Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Incyte Corporation 2022 Q1 - Results - Earnings Call Presentation

Incyte's (NASDAQ:INCY) Q1 2022 net income fell ~17% year over year to ~$122.9M on a non-GAAP basis as the biotech was hampered in the quarter by significant increases in operating expenses. Revenue of $733.24M was a ~21.3% year over year increase but still missed Street estimates. Sales of Ja...